Overcoming Barriers in Oncolytic Virotherapy with HDAC Inhibitors and Immune Checkpoint Blockade

Oncolytic viruses (OVs) target and destroy cancer cells while sparing their normal counterparts. These viruses have been evaluated in numerous studies at both pre-clinical and clinical levels and the recent Food and Drug Administration (FDA) approval of an oncolytic herpesvirus-based treatment raise...

Descripción completa

Detalles Bibliográficos
Autores principales: Marchini, Antonio, Scott, Eleanor M., Rommelaere, Jean
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2016
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4728569/
https://www.ncbi.nlm.nih.gov/pubmed/26751469
http://dx.doi.org/10.3390/v8010009

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4728569/
https://www.ncbi.nlm.nih.gov/pubmed/26751469
http://dx.doi.org/10.3390/v8010009

Ejemplares similares